Abstract:Circulation: Genomic and Precision Medicine, Ahead of Print. Background:Predictive performance of polygenic risk scores (PRS) varies across populations. To facilitate equitable clinical use, we developed PRS for coronary heart disease (CHD; PRSCHD) for 5 genetic ancestry groups.Methods:We derived ancestry-specific and multi-ancestry PRSCHDbased on pruning and thresholding and continuous shrinkage priors (polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods) applied to summary statistics from the largest multi-ancestry genome-wide association study meta-analysis for CHD to date, including 1.1 million participants from 5 major genetic ancestry groups. Following training and optimization in the Million Veteran Program, we evaluated the best-performing PRSCHDin 176 988 individuals across 9 diverse cohorts.Results:Multi-ancestry polygenic risk score for CHD developed using pruning and thresholding methods and polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods outperformed ancestry-specific Polygenic risk score for CHD developed using pruning and thresholding methods and polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods across a range of tuning values. Two best-performing multi-ancestry PRSCHD(ie, polygenic risk score for CHD developed using pruning and thresholding methods optimized using a multi-ancestry population and polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods optimized using a multi-ancestry population) and 1 ancestry-specific (PRSCSxEUR) were taken forward for validation. Polygenic risk score for CHD developed using pruning and thresholding methods (PT) optimized using a multi-ancestry population demonstrated the strongest association with CHD in individuals of South Asian genetic ancestry and European genetic ancestry (odds ratio per 1 SD [95% CI, 2.75 [2.41–3.14], 1.65 [1.59–1.72]), followed by East Asian genetic ancestry (1.56 [1.50–1.61]), Hispanic/Latino genetic ancestry (1.38 [1.24–1.54]), and African genetic ancestry (1.16 [1.11–1.21]). Polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods optimized using a multi-ancestry population showed the strongest associations in South Asian genetic ancestry (2.67 [2.38–3.00]) and European genetic ancestry (1.65 [1.59–1.71]), lower in East Asian genetic ancestry (1.59 [1.54–1.64]), Hispanic/Latino genetic ancestry (1.51 [1.35–1.69]), and the lowest in African genetic ancestry (1.20 [1.15–1.26]).Conclusions:The use of summary statistics from a large multi-ancestry genome-wide meta-analysis improved the performance of PRSCHDin most ancestry groups compared with single-ancestry methods. Despite the use of one of the largest and most diverse sets of training and validation cohorts to date, improvement of predictive performance was limited in African genetic ancestry. This highlights the need for larger Genome-wide association study datasets of underrepresented populations to enhance the performance of PRSCHD.

Improving reporting standards for polygenic scores in risk prediction studies

Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations

Implementing polygenic risk scores in the clinic

Recent advances in polygenic scores: translation, equitability, methods and FAIR tools

Methodologies underpinning polygenic risk scores estimation: a comprehensive overview

Polygenic risk scores: from research tools to clinical instruments

The expected polygenic risk score (ePRS) framework: an equitable metric for quantifying polygenetic risk via modeling of ancestral makeup

The Polygenic Score Catalog: an open database for reproducibility and systematic evaluation

Advancements and limitations in polygenic risk score methods for genomic prediction: a scoping review

Optimization of Multi-Ancestry Polygenic Risk Score Disease Prediction Models

The PRIMED Consortium: Reducing Disparities in Polygenic Risk Assessment

Clinical use of current polygenic risk scores may exacerbate health disparities

Principles and methods for transferring polygenic risk scores across global populations

Identifying and characterizing disease subpopulations that most benefit from polygenic risk scores

Clinical genetic counseling and translation considerations for polygenic scores in personalized risk assessments: A Practice Resource from the National Society of Genetic Counselors

A perspective on genetic and polygenic risk scores—advances and limitations and overview of associated tools

Polygenic risk scores for prediction of breast cancer and breast cancer subtypes

Multi-Ancestry Polygenic Risk Score for Coronary Heart Disease Based on an Ancestrally Diverse Genome-Wide Association Study and Population-Specific Optimization

Taking the risk. A systematic review of ethical reasons and moral arguments in the clinical use of polygenic risk scores

Current State and Future of Polygenic Risk Scores in Cardiometabolic Disease: A Scoping Review

Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues